Modified study designs to expand treatment options in personalised oncology: a multistakeholder view
Personalised oncology, whereby patients are given therapies based on their molecular tumour profile, is rapidly becoming an essential part of optimal clinical care, at least partly facilitated by recent advances in next-generation sequencing-based technology using liquid- and tissue-based biopsies....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2023
|
| In: |
European journal of cancer
Year: 2023, Volume: 194, Pages: 1-15 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2023.113278 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2023.113278 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804923003805 
|
| Author Notes: | Christophe Le Tourneau, Fabrice André, Åslaug Helland, Linda Mileshkin, Warnyta Minnaard, Anja Schiel, Kjetil Taskén, David M. Thomas, Maria Luisa Veronese, Gonzalo Durán-Pacheco, Lada Leyens, Kaspar Rufibach, Marlene Thomas, Alwin Krämer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1879390523 | ||
| 003 | DE-627 | ||
| 005 | 20240325174202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240129s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2023.113278 |2 doi | |
| 035 | |a (DE-627)1879390523 | ||
| 035 | |a (DE-599)KXP1879390523 | ||
| 035 | |a (OCoLC)1425207337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Le Tourneau, Christophe |e VerfasserIn |0 (DE-588)1317471377 |0 (DE-627)1879391287 |4 aut | |
| 245 | 1 | 0 | |a Modified study designs to expand treatment options in personalised oncology |b a multistakeholder view |c Christophe Le Tourneau, Fabrice André, Åslaug Helland, Linda Mileshkin, Warnyta Minnaard, Anja Schiel, Kjetil Taskén, David M. Thomas, Maria Luisa Veronese, Gonzalo Durán-Pacheco, Lada Leyens, Kaspar Rufibach, Marlene Thomas, Alwin Krämer |
| 264 | 1 | |c November 2023 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 4 August 2023, Version des Artikels 10 October 2023 | ||
| 500 | |a Gesehen am 29.01.2024 | ||
| 520 | |a Personalised oncology, whereby patients are given therapies based on their molecular tumour profile, is rapidly becoming an essential part of optimal clinical care, at least partly facilitated by recent advances in next-generation sequencing-based technology using liquid- and tissue-based biopsies. Consequently, clinical trials have shifted in approach, from traditional studies evaluating cytotoxic chemotherapy in largely histology-based populations to modified, biomarker-driven studies (e.g. basket, umbrella, platform) of molecularly guided therapies and cancer immunotherapies in selected patient subsets. Such modified study designs may assess, within the same trial structure, multiple cancer types and treatments, and should incorporate a multistakeholder perspective. This is key to generating complementary, fit-for-purpose and timely evidence for molecularly guided therapies that can be used as proof-of-concept to inform further study designs, lead to approval by regulatory authorities and be used as confirmation of clinical benefit for health technology assessment bodies. In general, the future of cancer clinical trials requires a framework for the application of innovative technologies and dynamic design methodologies, in order to efficiently transform scientific discoveries into clinical utility. Next-generation, modified studies that involve the joint efforts of all key stakeholders will offer individualised strategies that ultimately contribute to globalised knowledge and collective learning. In this review, we outline the background and purpose of such modified study designs and detail key aspects from a multistakeholder perspective. We also provide methodological considerations for designing the studies and highlight how insights from already-ongoing studies may address current challenges and opportunities in the era of personalised oncology. | ||
| 650 | 4 | |a Adaptive clinical trial | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Stakeholder participation | |
| 700 | 1 | |a André, Fabrice |e VerfasserIn |4 aut | |
| 700 | 1 | |a Helland, Åslaug |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mileshkin, Linda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Minnaard, Warnyta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schiel, Anja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taskén, Kjetil |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, David M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Veronese, Maria Luisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Durán-Pacheco, Gonzalo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leyens, Lada |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rufibach, Kaspar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Marlene |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 194(2023) vom: Nov., Artikel-ID 113278, Seite 1-15 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Modified study designs to expand treatment options in personalised oncology a multistakeholder view |
| 773 | 1 | 8 | |g volume:194 |g year:2023 |g month:11 |g elocationid:113278 |g pages:1-15 |g extent:15 |a Modified study designs to expand treatment options in personalised oncology a multistakeholder view |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2023.113278 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |7 1 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804923003805 |x Verlag |z lizenzpflichtig |3 Volltext |7 1 |
| 951 | |a AR | ||
| 992 | |a 20240129 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |e 910000PK1067780025 |e 910100PK1067780025 |k 0/910000/ |k 1/910000/910100/ |p 14 |y j | ||
| 999 | |a KXP-PPN1879390523 |e 4471832166 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1016/j.ejca.2023.113278"],"eki":["1879390523"]},"title":[{"subtitle":"a multistakeholder view","title_sort":"Modified study designs to expand treatment options in personalised oncology","title":"Modified study designs to expand treatment options in personalised oncology"}],"recId":"1879390523","note":["Online verfügbar 4 August 2023, Version des Artikels 10 October 2023","Gesehen am 29.01.2024"],"physDesc":[{"extent":"15 S."}],"person":[{"roleDisplay":"VerfasserIn","family":"Le Tourneau","given":"Christophe","role":"aut","display":"Le Tourneau, Christophe"},{"family":"André","roleDisplay":"VerfasserIn","display":"André, Fabrice","role":"aut","given":"Fabrice"},{"given":"Åslaug","role":"aut","display":"Helland, Åslaug","roleDisplay":"VerfasserIn","family":"Helland"},{"family":"Mileshkin","roleDisplay":"VerfasserIn","display":"Mileshkin, Linda","role":"aut","given":"Linda"},{"given":"Warnyta","display":"Minnaard, Warnyta","role":"aut","roleDisplay":"VerfasserIn","family":"Minnaard"},{"family":"Schiel","roleDisplay":"VerfasserIn","given":"Anja","display":"Schiel, Anja","role":"aut"},{"family":"Taskén","roleDisplay":"VerfasserIn","given":"Kjetil","display":"Taskén, Kjetil","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Thomas","display":"Thomas, David M.","role":"aut","given":"David M."},{"given":"Maria Luisa","role":"aut","display":"Veronese, Maria Luisa","family":"Veronese","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Durán-Pacheco","role":"aut","display":"Durán-Pacheco, Gonzalo","given":"Gonzalo"},{"given":"Lada","display":"Leyens, Lada","role":"aut","roleDisplay":"VerfasserIn","family":"Leyens"},{"roleDisplay":"VerfasserIn","family":"Rufibach","given":"Kaspar","role":"aut","display":"Rufibach, Kaspar"},{"family":"Thomas","roleDisplay":"VerfasserIn","given":"Marlene","role":"aut","display":"Thomas, Marlene"},{"roleDisplay":"VerfasserIn","family":"Krämer","given":"Alwin","display":"Krämer, Alwin","role":"aut"}],"name":{"displayForm":["Christophe Le Tourneau, Fabrice André, Åslaug Helland, Linda Mileshkin, Warnyta Minnaard, Anja Schiel, Kjetil Taskén, David M. Thomas, Maria Luisa Veronese, Gonzalo Durán-Pacheco, Lada Leyens, Kaspar Rufibach, Marlene Thomas, Alwin Krämer"]},"relHost":[{"recId":"266883400","pubHistory":["28.1992 -"],"titleAlt":[{"title":"EJC online"}],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer","roleDisplay":"Herausgebendes Organ"},{"roleDisplay":"Herausgebendes Organ","display":"European Association for Cancer Research","role":"isb"},{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European School of Oncology"}],"id":{"issn":["1879-0852"],"eki":["266883400"],"zdb":["1468190-0"]},"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"disp":"Modified study designs to expand treatment options in personalised oncology a multistakeholder viewEuropean journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press"}],"language":["eng"],"part":{"year":"2023","extent":"15","pages":"1-15","text":"194(2023) vom: Nov., Artikel-ID 113278, Seite 1-15","volume":"194"}}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"November 2023"}]} | ||
| SRT | |a LETOURNEAUMODIFIEDST2023 | ||